Search results for " pandemic"

showing 10 items of 270 documents

The Synergistic Impacts of Anthropogenic Stressors and COVID-19 on Aquaculture: A Current Global Perspective

2021

13 pages, 6 figures, 2 tables.-- This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License

010504 meteorology & atmospheric sciencesNatural resource economicsSocio-ecological systemsvulnerabilityVulnerabilitySARS (Disease)01 natural sciencesFood security -- Case studiesStakeholder perceptionsCOVID-19 (Disease)Aquaculturefood insecurityStakeholderPerceptionsClimate changeZoologíastakeholders perceptions2. Zero hunger04 agricultural and veterinary sciencesSARS-COV2-pandemicmultiple stressorsFood insecurityclimate change2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)VulnerabilityClimate changesocio-ecological systemManagement Monitoring Policy and LawAquatic Science14. Life underwaterSARS-CoV-2 pandemic ; supply chain ; food insecurity ; climate change ; multiple stressors ; vulnerability ; stakeholder perceptions ; socioecological systemsMultiple stressorssupply chainEcology Evolution Behavior and Systematics0105 earth and related environmental sciencesFood insecuritybusiness.industryPerspective (graphical)Stressorclimate change food insecurity multiple stressors SARS-CoV-2 pandemic socio-ecological systems stakeholder perceptions supply chain vulnerabilitySocioecological systemsVulnerability model of recoveryClimatic changesSupply chain13. Climate action040102 fisheriesBusiness logistics -- Case studies0401 agriculture forestry and fisheriesEnvironmental scienceSARS-CoV-2 pandemicbusiness
researchProduct

Advancing Through the Pandemic From the Perspective of Marine Graduate Researchers: Challenges, Solutions, and Opportunities

2020

The ongoing COVID-19 pandemic has brought about a new social and academic reality to researchers worldwide. The field of marine science, our own topic of interest, has also been impacted in multiple ways, from cancelation of laboratory and field activities to postponement of onboard research. As graduate researchers, we have a time-sensitive academic path, and our current situation may constrain our academic future. At the same time, the pandemic demands revised strategies to deal with the ongoing difficulties and tackle similar future situations. In this perspective, we have gathered information on the challenges, solutions and opportunities for graduate researchers in the field of marine …

0106 biological sciences2019-20 coronavirus outbreaklcsh:QH1-199.5010504 meteorology & atmospheric sciencesCoronavirus disease 2019 (COVID-19)Ocean Engineeringlcsh:General. Including nature conservation geographical distributionAquatic ScienceOceanography01 natural sciencesopportunitiescareerPolitical sciencePandemicSocial mediaearly career researcherslcsh:Sciencecoronavirus pandemic0105 earth and related environmental sciencesWater Science and TechnologyAcademic careerGlobal and Planetary Change010604 marine biology & hydrobiologyField (Bourdieu)PostponementPerspective (graphical)VDP::Matematikk og Naturvitenskap: 400marine science and technologylcsh:QEngineering ethicsFrontiers in Marine Science
researchProduct

Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directo…

2020

Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present…

0301 basic medicineAngiotensin-Converting Enzyme InhibitorsDiseaseoutcomescardiovascular diseases; COVID-19; hypertension; infection; outcomes; Betacoronavirus; COVID-19; Cardiovascular Diseases; Humans; Hypertension; Italy; SARS-CoV-2; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Coronavirus Infections; Pandemics; Pneumonia Viral; Renin-Angiotensin SystemRenin-Angiotensin System0302 clinical medicinecardiovascular diseaseViralAngiotensin Receptor AntagonistsbiologyAngiotensin Receptor AntagonistAntihypertensive AgentItalyoutcomeAngiotensin Receptor BlockersCoronavirus InfectionsCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyhypertensionCoronavirus disease 2019 (COVID-19)Pneumonia ViralBetacoronavirusAngiotensin Receptor Antagonists03 medical and health sciencesPharmacotherapyRenin–angiotensin systemInternal MedicinemedicineHumansIntensive care medicinePandemicsAntihypertensive Agentsoutcomes.BetacoronaviruPandemicCoronavirus InfectionSARS-CoV-2business.industryOutbreakCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin-converting enzymePneumoniacardiovascular diseases; COVID-19; hypertension; infection; outcomesinfectioncardiovascular diseases030104 developmental biologybiology.proteincardiovascular diseases; COVID-19; hypertension; infection; outcomes; betacoronavirus; cardiovascular diseases; humans; hypertension; Italy; angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; antihypertensive agents; coronavirus infections; pandemics; pneumonia viral; renin-angiotensin systembusiness030217 neurology & neurosurgery
researchProduct

The impact of physical activity on psychological health during Covid-19 pandemic in Italy

2020

The worldwide spread of COVID-19 has upset the normality of Italian daily life, forcing population to social distancing and self-isolation. Since the containment precautions also concern sport-related activities, home workout remained the only possibility to play sports and stay active during the pandemic. The present study aimed to examine changes in the physical activity levels during self-quarantine in Italy, and the impact of exercise on psychological health. A total of 2974 Italian subjects has completed an online survey, but only 2524 subjects resulted eligible for this study. The questionnaire measured the total weekly physical activity energy expenditure before and during quarantine…

0301 basic medicineHome based exercisemedicine.medical_specialtyEpidemiologyPopulationMetabolic equivalentArticlePsychological well-beingExercise Epidemiology Public health Psychology COVID-19 Pandemic Quarantine Physical activity Home based exercise IPAQ-SF Psychological well-being PGWBI03 medical and health sciences0302 clinical medicineEpidemiologyIPAQ-SFmedicinePsychologylcsh:Social sciences (General)educationlcsh:Science (General)Exerciseeducation.field_of_studyPublic healthMultidisciplinaryPandemicbusiness.industryPhysical activityPublic healthSocial distanceCOVID-19PGWBIMental health030104 developmental biologyCOVID-19 Epidemiology Exercise Home based exercise IPAQ-SF Pandemic PGWBI Psychological well-being Psychology Physical activity Public health QuarantinePsychological well-beingWell-beingQuarantinelcsh:H1-99business030217 neurology & neurosurgeryDemographylcsh:Q1-390Heliyon
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

2018

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. Funding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in…

0301 basic medicineMalePediatricsEpidemiologyvirusesInfluenza B viruinfluenza ; influenza vaccine effectiveness ; influenza vaccination ; case control study ; multicentre study ; EuropeEurope case control study influenza influenza vaccination influenza vaccine effectiveness multicentre study0302 clinical medicineInfluenza A Virus H1N1 Subtype[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInteriminfluenza vaccine effectivenessEpidemiologyPandemicInfluenza A Virus030212 general & internal medicineQAInfluenza vaccine effectivenessChildmedia_commonVaccine EffectivenessVaccinationvirus diseasesMiddle Agedinfluenza vaccinationmulticentre study3. Good healthVaccinationEuropeTreatment OutcomeInfluenza VaccinesChild PreschoolH3N2 SubtypeFemaleSeasonsInfluenza VaccineinfluenzaRapid CommunicationHumanAdultRMmedicine.medical_specialtyAdolescentInfluenza vaccine030106 microbiologyCase control studyMulticentre studyEuropean studiesSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA03 medical and health sciencesVirologyInfluenza Humanmedicinemedia_common.cataloged_instanceHumansH1N1 SubtypeVacina AntigripalEuropean UnionEuropean unionPreschoolPandemicsAgedPandemicInfluenza A Virus H3N2 SubtypeCuidados de SaúdePublic Health Environmental and Occupational HealthInfant NewbornInfantInfluenza ainfluenza vaccine effectivenecase control studyNewbornEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre studyInfluenzarespiratory tract diseasesInfluenza vaccinationInfluenza B virusEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study; Adolescent; Adult; Aged; Child; Child Preschool; Europe; European Union; Female; Humans; Infant; Infant Newborn; Influenza A Virus H1N1 Subtype; Influenza A Virus H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza Human; Male; Middle Aged; Pandemics; Treatment Outcome; Vaccination; Seasons[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDeterminantes da Saúde e da Doença[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment

2020

Abstract The ongoing outbreak of the novel coronavirus (SARS‐CoV‐2) infection is creating serious challenges for health laboratories that seek to identify viral infections as early as possible, optimally at the earliest appearance of symptom. Indeed, there is urgent need to develop and deploy robust diagnostic methodologies not only to use in health laboratory environments but also directly in places where humans circulate and spread the virus such as airports, trains, boats, and any public aggregation places. The success of a reliable and sensitive asymptomatic diagnosis relies on the identification and measurement of informative biomarkers from human host and virus in a rapid, sensitive, …

0301 basic medicineportableSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralImmunologycoronavirusBiologymedicine.disease_causeSensitivity and SpecificityDisease OutbreaksWorkflowBetacoronavirus03 medical and health sciencesCOVID-19 Testing0302 clinical medicinePandemicmedicineAnimalsHumansMass ScreeninginstrumentImmunology and AllergyBiomarker discoveryAsymptomatic InfectionsPandemicsdeviceMass screeningCoronavirusInvited ReviewClinical Laboratory TechniquesSARS-CoV-2COVID-19Reproducibility of ResultsClinical Laboratory Servicescoronavirus; device; instrument; portable; SARS-CoV-2 detection; Animals; Asymptomatic Infections; Betacoronavirus; Biomarkers; Clinical Laboratory Services; Clinical Laboratory Techniques; Coronavirus Infections; Disease Outbreaks; Humans; Mass Screening; Pandemics; Pneumonia Viral; Reproducibility of Results; Sensitivity and Specificity; WorkflowIdentification (information)030104 developmental biologyWorkflowRisk analysis (engineering)SARS‐CoV‐2 detectionCoronavirus InfectionsHost (network)Biomarkers030215 immunology
researchProduct

Managing stress during the coronavirus disease 2019 pandemic and beyond: Reappraisal and mindset approaches

2020

The novel coronavirus disease 2019 (COVID‐19) pandemic is a global public health crisis of a scale not previously experienced in modern times (Kickbusch et al., 2020). Governmental ‘lockdown’ measures aimed at minimizing virus transmission including ‘stay at home’ orders, closure of businesses and places of congregation, and travel restrictions have had a substantive societal impact that permeates almost every facet of daily life (Gostin & Wiley, 2020; Shanafelt, Ripp, & Trockel, 2020). These widespread changes represent considerable sources of stress in the population and will have deleterious effects on mental and physical health going forward. As nations begin to emerge from ‘lockdown’, …

050103 clinical psychologyPsychological interventionMindsetPandemicstress mindsetPsychologyViralApplied PsychologyinterventionPsychiatryeducation.field_of_study05 social sciencesSocietal impact of nanotechnologyCOVID‐19 pandemicGeneral MedicinePsychiatry and Mental healthClinical PsychologySocial IsolationQuarantinePublic Health and Health ServicesCoronavirus Infectionsmedicine.medical_specialtyPopulationPneumonia ViralCOVID-19 pandemicStressBetacoronavirusPolitical science0502 economics and businessDevelopment economicsmedicineHumans0501 psychology and cognitive sciencesClosure (psychology)educationPandemicsSARS-CoV-2Public healthBusiness and ManagementCOVID-19PneumoniareappraisalMental healthstress appraisalSelf CareCommentaryPsychological050203 business & managementStress PsychologicalStress and Health
researchProduct

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN…

2020

Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely…

2019-20 coronavirus outbreakCancer ResearchPneumonia ViralDiseasesSevere Acute Respiratory Syndromemedicine.disease_causeBetacoronavirusMyeloproliferative DisordersNeoplasmsSurveys and QuestionnairesPandemicmedicineHumansPandemicsCoronavirusPhiladelphia negativeMyeloproliferative DisordersbiologySARS-CoV-2business.industryHealth careCOVID-19Hematologymedicine.diseasebiology.organism_classificationVirologyCoronavirusPneumoniaItalyOncologyPerspectiveCoronavirus InfectionsbusinessCoronavirus InfectionsBetacoronavirusBetacoronavirus COVID-19 Humans Italy SARS-CoV-2 Surveys and Questionnaires Coronavirus Coronavirus Infections Myeloproliferative Disorders Neoplasms Pandemics Pneumonia Viral Severe Acute Respiratory Syndrome
researchProduct